Gram-negative sepsis syndrome is an increasingly common complication in medical and surgical patients. The molecular and cellular mechanisms underlying this dreaded complication are yielding to investigation. These studies have led to a multiplicity of targets for novel therapies. Despite highly promising results in many animal studies, clinical studies have been disappointing.
Bibliographical noteFunding Information:
This work was supported in part by grants from North Trauma Institute, North Memorial Health Care, and the Department of Defense.
Copyright 2018 Elsevier B.V., All rights reserved.